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Background: Fludarabine is a common constituent of con-
ditioning for hematopoietic cell transplantation (HCT). It is a
prodrug that is dephosphorylated in plasma to its measur-
able metabolite, F-ara-A, which after intracellular rephos-
phorylation interferes with DNA replication, transcription
and translation, and induces apoptosis.
Due to variable renal clearance, F-ara-A levels on day 0 are
variable. The clinical relevance of the F-ara-A persisting in
plasma is unknown. The goal of this study was to assess the
relationship between F-ara-A levels on day 0 and clinical
outcomes including GVHD, infections, relapse and death.
Patients and Methods: We included 166 consecutive
patients undergoing ﬁrst allogeneic transplantation of ﬁl-
grastim-mobilized blood stem cells for a hematologic ma-
lignancy between December 2008 and 2012. Conditioning
was myeloablative, and included ﬂudarabine (50 mg/m2
daily from days -6 to -2), busulfan and antithymocyte glob-
ulin. Additional GVHD prophylaxis included methotrexate
and cyclosporine. The interval between the last ﬂudarabine
dose and graft infusion was 48-72 hours. F-ara-A serum
levels were measured using mass spectrometry.
Results: In univariate analyses, there was no difference in
median F-ara-A levels between patients who did vs did not
develop acute GVHD grade 2-4, acute GVHD grade 3-4, any
chronic GVHD, chronic GVHDneeding systemic therapy (NST),
CMV reactivation above our threshold for preemptive therapy
(25,000 IU/mL), post-transplant lymphoproliferative disorder
(PTLD), relapse, death or non-relapse death (Figure 1).
In multivariate analyses, there was no difference in the
likelihood of developing any one of the outcomes between
patients whose F-ara-A level was above vs below median (14
ng/mL). We also assessed for differences in the likelihood of
developing each outcome between patients with levels in
the fourth quartile (21-104 ng/mL) vs the ﬁrst quartile (1-9
ng/mL). Again, in this analysis, there was no difference for
any outcome.
We also noted a weak correlation between F-ara-A levels
on day 0 and the day of neutrophil engraftment (r¼0.16,
p¼0.04), and a trend towards more bacterial infections in
patients with F-ara-A levels in the fourth vs ﬁrst quartile.
Discussion: The results suggest that there is no or minimal
impact of day 0 F-ara-A levels on clinical outcomes. This may
be due to the fact that F-ara-A levels on day 0 were relatively
low (1-104 ng/mL, median 14 ng/mL) compared to levels 1-4
hours after ﬂudarabine infusion (w1,000 ng/mL).
Conclusion: Day 0 F-ara-A levels are highly variable (1-104
ng/mL), likely due to variable renal function. Given that we
found no association between the day 0 levels and clinical
outcomes we do not support delaying graft infusion until F-
ara-A level has dropped below a certain level, as long as the
last ﬂudarabine dose is given within 48 hours of graft infu-
sion and to patients with normal renal function.347
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Background: Allogeneic hematopoietic stem-cell trans-
plantation (allo-HSCT) is a potentially curative treatment for
a variety of hematologic malignancies and nonmalignant
hematologic disorders. However, only about a third of
candidates for allo-HSCT have HLA-matched siblings. For
patients who lack HLA-matched siblings, partially HLA-mis-
matched (haploidentical) related donors are good alternative
sources of stem cells for allo-HSCT. In this retrospective,
single center study we evaluated safety and efﬁcacy of hap-
loidentical allo-HSCT compared to those of HLA-matched
allo-HSCT in patients with acute leukemia.
Methods: A total of 94 acute leukemia patients with a mean
age of 37 years who underwent allo-HSCT between June
2010 and November 2012 were analyzed. All patients
received Cyclophosphamide (Cy) 50 mg/kg i.v. on days +3
and +4. Pharmacologic prophylaxis of GvHD with cyclo-
sporine-A (CsA) and mycophenolate mofetil (MMF) was not
initiated until day +5 to avoid blocking Cy-induced tolerance.
All patients received CsAwhich was initiated at a dose of 400
mg/day, and then adjusted according to the plasma levels. If
there was no GvHD, it was tapered off by day +180. In
addition to CsA, all haploidentical allo-HSCT recipients
received MMF until day +35 at a dose of 1 gr/day.
Results: There were no signiﬁcant differences in age, sex,
type of acute leukemia, disease status up-front HSCT, or
transplant characteristics between the groups except a
higher median number of stem cells infused in hap-
loidentical group (p¼0.002). The median follow-up was 194
(range 88-372) days for haploidentical group and 210 (range
105-417) days for HLA-matched group. 98% of the patients
engrafted. The median time to neutrophil and thrombocyte
engraftments were signiﬁcantly longer in the haploidentical
group compared to the HLA-matched group (neutrophil
engraftment; 20 days vs 16 days, respectively, p¼ 0.006)
(thrombocyte engraftment; 18 days vs 16 days, respectively,
p¼0.015). The incidence of acute GvHD >¼ 2 was 56% in
haploidentical group and 19% in HLA-matched group
(p¼0.001). The incidence of documented viral infections was
signiﬁcantly higher in the haploidentical group compared to
the HLA-matched group (42% vs 11%, respectively, p¼0.001).
The relapse rates as well as the overall mortality rates (at 100
days and 1 year) were not signiﬁcantly different between the
two groups.
Conclusion: Our results suggest that haploidentical allo-
HSCT is a safe treatment modality in patients with acute
leukemia who lack HLA-matched siblings. The major prob-
lems are seems to be viral infections and acute GvHD. Future
challenges remain in improving post-transplant immune
reconstitution and ﬁnding the best approach to reduce the
incidence and severity of GvHD and infections, while pre-
serving graft-versus-leukemia effect to prevent the recur-
rence of the underlying disease.348
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PTLD is a serious complication of iatrogenic immunosup-
pression, typically in the setting of solid organ trans-
plantation. For patients undergoing allogeneic stem cell
transplant. Potential risk factors include a T-cell depleted
graft, , HLA-mismatch, and GVHD.
Patients and Methods: We searched for PTLD occurrence
among 68 consecutive haplo-cord stem cell transplant re-
cipients treated at The University of Chicago in order to
describe its incidence, patient-, disease- and treatment-
related characteristics. Haplo-cord transplantation consisted
of a single cord blood unit augmented by a CD34+ selected
haploidentical G-CSF mobilized peripheral blood stem cell
graft from a related donor. Conditioning consisted of ﬂu-
darabine, melphalan and rabbit ATG. After the 3rd noted
PTLD, routine PCR monitoring of peripheral blood for EBV
was implemented.. Further evaluation for PTLD was as clin-
ically indicated, usually prompted by high EBV PCR copy
number with or without associated symptoms.
Results: 68 patients (med age 48 yrs, range 4-69) underwent
haplo-cord transplantation; 8 patients (11.8%) were subse-
quently diagnosed with PTLD based on either clinical (n¼3)
or pathologically-proven (n¼5) criteria. All haploidentical
donors for the 8 PTLD patients had positive EBV serologies.
The median age of these 8 patients was 39 yrs (range, 28-51).
The median time from transplantation to development of
PTLD was 103 days (range, 68-164d). Among 4 patients with
a pathologically-conﬁrmed diagnosis, morphology was EBV+
monomorphic DLBCL, while a 5th patient had ﬂow cytom-
etry-based diagnosis showing a monomorphic lambda
restricted B-PTLD. All patients with biopsy-proven PTLD
were also strongly CD30+ with diffuse staining pattern. In 3
patients, the diagnosis of PTLDwas based on rapid rise of EBV
titers along with new onset adenopathy. The median EBV
viral load peak of all patients with PTLD was 2.39 million
(range, 23,000 to 10 million). There were no differences in
age, gender, or proportionwith lymphoid or myeloid disease.
All patients were treated with reduction of immunosup-
pression plus rituximab; one patient with CNS lesions was
treatedwith R-CHOP x 4 plus intrathecal methotrexate and is
currently in remission. 3 pts have died, including 2 deaths
due to PTLD.
Summary: PTLD is a common complication following haplo-
cord transplantation, likely related to ATG treatment and
HLA mismatch in the cord blood setting. We advocate close
EBV surveillance and prompt rituximab treatment for this
approach. The observation that CD30 positivity is common
raises the possibility that brentuximab vedotin could be used
along with other standard approaches in management.349
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Chronic Graft versus Host Disease (CGVHD) is an autoim-
mune-like disorder that remains the main cause of non-
relapse morbidity and mortality following allogeneic
hematopoietic stem cell transplantation (alloHSCT), yet its
pathogenic mechanisms remain poorly understood. To
identify the systemic cytokine pathways supporting the
development and persistence of CGVHD, we performed
microarray analysis on sorted monocytes from normal con-
trols (NC) and patients with severe cutaneous involvement,
including both lichenoid and sclerotic CGVHD. Monocytes
were chosen as in vivo reporter cells, capable of upregulating
distinct patterns of gene expression in response to different
cytokines. Two main pathways were determined to be
signiﬁcantly upregulated. (1) Interferon (IFN)-inducible
genes including those involved in signaling, anti-viral func-
tion, lymphocyte homeostasis and trafﬁcking, apoptosis and
antigen uptake and presentation (STAT1, GBP1, IL15,
TNFSF13B, CXCL10, TNFSF10, FCGR1A, MSR1, TAP1). (2) Upre-
gulation of innate immune TLR/RIG1/CLR receptors that can
respond to pathogens or cell damage by triggering IFN pro-
duction and inﬂammasome formation (TLR2, TLR4, AIM2,
DDX58, IFIH1, CLEC4E). Based on the microarray proﬁle, we
designed a multiplex RNA analysis probe set to test gene
expression in monocytes from (1) CGVHD patients with a
broad range of organ involvement, (2) alloHSCT patients
without clinical signs of CGVHD (NP) and (3) normal controls
(NC). The genes involved in IFN induced and innate immune
pathways that were identiﬁed by microarray analysis were
veriﬁed in this more quantitative analysis in 75 CGVHD, 14
NP and 20 NC; comparable upregulation of these pathways
was found in patients with extensive lichenoid or sclerotic
CGVHD. Furthermore, these pathways were substantiated in
ELISA assays by elevated levels of IFN induced chemokines
(CXCL9, CXCL10) and cytokines (BAFF) in CGVHD patient
plasma, and were consistent with increased levels of Type I
Interferon producing cells and IFN-induced factors (MXA,
CXCL9) in inﬂammatory inﬁltrates in CGVHD targeted tis-
sues. These results suggest that IFN induced by the innate
immune system’s response to damage associated molecular
patterns (DAMP) could initiate and contribute to a sustained
inﬂammatory process in CGVHD.350
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MDS/MPN are hematopoietic malignancies with both
dysplastic and proliferative features. Therapeutic options are
limited, with low probabilities and durations of remission.
Allogeneic HCT is the only potentially curative treatment;
however few data on outcomes and risk factors for survival
inMDS/MPN have been reported.We thus evaluated our HCT
experience with MDS/MPN.
